CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...